Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DB-H2
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DB-H2 is a hexane extract derived from the bark region of *Dioscorea batatas Decne*, a Chinese yam. It has demonstrated anti-atherosclerotic properties by significantly reducing atherosclerotic lesion area and lowering plasma levels of total cholesterol, oxidized-low-density lipoprotein, and c-reactive protein. Its mechanism of action involves inhibiting tumor necrosis factor (TNF)-α-induced vascular cell adhesion molecule-1 (VCAM-1) expression and monocyte adhesion, as well as suppressing nitric oxide (NO) and reactive oxygen species (ROS) production and inducible nitric oxide synthase (iNOS) expression in macrophages. These actions suggest its potential as a preventive agent against atherosclerosis.
Beyond the preview
Go deeper on DB-H2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DB-H2.